A cohort of 275, 164 T2DM patients found no evidence for altered cancer risk for repaglinide or α-glucosidase inhibitors compared to insulin-based therapies or other oral glucose-lowering drugs [216]. The gene discussed is INS; the disease is type 2 diabetes mellitus.